AI-Bio
PrivateBest-engineered enzymatic-DNA-synthesis platform with a tier-1 crossover cap table — but ~4 years since its last equity raise, a founder-out / outside-operator reset, and a razor-and-blades instrument fighting Twist's column-scale economics make this a WATCHING name, not a buy; the IPO window stays shut until it proves an installed base and recurring-reagent pull, and a down-round (or strategic sale) is the more likely next print than an S-1.
Research
The verdict
Best-engineered enzymatic-DNA-synthesis platform with a tier-1 crossover cap table — but ~4 years since its last equity raise, a founder-out / outside-operator reset, and a razor-and-blades instrument fighting Twist's column-scale economics make this a WATCHING name, not a buy; the IPO window stays shut until it proves an installed base and recurring-reagent pull, and a down-round (or strategic sale) is the more likely next print than an S-1.
DNA Script is a Paris-founded (2014), now dual-Paris/South-San-Francisco synthetic-biology tools company whose single product is the SYNTAX DNA printer — a benchtop instrument that lets a lab synthesize its own DNA oligonucleotides on-site, on-demand, instead of ordering them from a centralized supplier like Twist Bioscience or IDT.
The technology is the thing to understand. Essentially all commercial DNA today is made by phosphoramidite chemistry — a 40-year-old, four-step chemical cycle run in harsh organic solvents, industrialized at column/array scale by Agilent, Twist and IDT. DNA Script instead pioneered Enzymatic DNA Synthesis (EDS): engineered terminal deoxynucleotidyl transferase (TdT) enzymes add bases one at a time in mild, aqueous, open-air conditions — no toxic solvents, faster cycle chemistry, and crucially deployable on a benchtop rather than only in a chemistry plant. Ybert's framing — "DNA is the next silicon" — positions EDS as the enabling "fab in a box" for synthetic biology.
Business model — razor-and-blades. Revenue has three legs:
Customers — molecular-biology and genomics labs (academic core labs, pharma/biotech R&D), with stated workflows in endpoint PCR, qPCR, amplicon sequencing, mutagenesis, gene assembly, CRISPR guide synthesis, and protein engineering. Named flagship partner: Moderna (DARPA NOW program, see Lens 8). Suppliers — the value chain is enzyme engineering + reagent chemistry + instrument hardware/robotics + microfluidic consumables (see Lens 2). Competitors — phosphoramidite incumbents (Twist, IDT, Agilent, GenScript, Eurofins) on the demand they displace, and a clutch of fellow EDS challengers (Ansa, Molecular Assemblies, Camena, Evonetix, Telesis Bio) on the technology.
DNA Script sits in the middle of the chain — it is itself a picks-and-shovels supplier to the synthetic-biology and genomics economy — so the chain runs inputs → DNA Script → the lab → the lab's downstream output:
Upstream inputs into DNA Script:
DNA Script (the node): integrates enzymes + nucleotides + hardware + software into the SYNTAX system; manufactures/QCs reagent kits. VP Operations & Supply Chain: Bruno Larida.
Downstream — the buyers and channel:
Chokepoints / single-source dependencies: (1) The engineered TdT enzyme is the single-source dependency — proprietary, internal, the basis of every printed base; if a competitor's enzyme out-performs (longer reads, lower error, cheaper), the whole stack is leapfrogged. (2) The instrument itself is the customer chokepoint — once a lab buys SYNTAX, its reagents are locked to DNA Script (switching cost), but conversely DNA Script is locked to its own CM for hardware. (3) Strategic-investor suppliers Danaher Life Sciences and Agilent are both cap-table investors and the incumbents whose chemistry EDS displaces — a notable conflict that doubles as optionality (a strategic acquirer is pre-seated on the cap table; see Lens 7).
The bull's moat thesis — four layers:
patents/ dir exists in the research layer but is empty — count not verified) [n/a].Bargaining power — honest read: DNA Script's bargaining power over customers is structurally weak at the point of sale and strong only after. Pre-sale it must out-argue a cheaper, higher-throughput, zero-capex incumbent service (just order from Twist). Post-sale, the reagent lock-in flips power its way — but only for labs that genuinely need on-site speed/IP-confidentiality enough to pay an instrument premium. That is a niche, not a mass market: the value prop (same-day oligos, sequence confidentiality, no backorders) is real but addresses a subset of demand. Over suppliers (enzyme/chemistry it makes itself; hardware it contracts) power is moderate. Verdict on the moat: the technology moat is real but narrowing (Ansa+IDT, Molecular Assemblies, Evonetix are all advancing EDS); the durable moat is the installed base × reagent pull, which is unproven in the public record. A moat you can't measure is a moat you can't underwrite.
No segment financials exist — DNA Script is private and discloses no revenue, geographic, or product-line breakout [n/a — private, not disclosed; segments.csv is header-only]. Qualitatively, the business has three conceptual segments, none quantified:
No earnings exist. The "performance print" for a private deep-tech name is its financing trajectory, and here the tape is concerning — the music stopped ~4 years ago.
| Round | Date | Amount | Lead / notable | Source |
|---|---|---|---|---|
| Seed + Series A | 2014–2018 | ~$15M cumulative est. | Kurma, Idinvest, Sofinnova-adjacent | |
| Series B | 2019 | ~$38.5M / €34.5M | Illumina Ventures, Merck/M Ventures, LSP | |
| Series C — tranche 1 | Oct 2021 | $165M | Coatue + Catalio; Fidelity, Columbia Threadneedle, ArrowMark, Farallon, Moore; w/ Casdin, LSP, Illumina V, Bpifrance, Danaher LS, Agilent, M Ventures, Kurma, Alexandria | |
| Series C — tranche 2 | Jan 2022 | +$35M (→ "$200M Series C" total) | T. Rowe Price, Baillie Gifford, HealthCor, eureKARE, Irving | |
| DARPA grant | 2023 | up to $5M (non-dilutive) | DARPA NOW (via Moderna pgm) |
Cumulative equity raised: ~$280M (the figure most sources reconcile to: $165M + $35M + prior rounds); some aggregators cite $315–324M (likely including grants/debt).
The signal that matters: the last equity round closed January 2022. As of mid-2026 that is ~4.5 years with no disclosed new equity — an eternity for a capital-intensive instruments company that was burning to commercialize. Either (a) the 2022 raise was large enough to still be funding operations (plausible — $200M is real money for a ~150-person company), or (b) a raise has happened privately and quietly (no evidence found), or (c) the company has not been able to raise on acceptable terms in the post-2022 synbio winter (see Lens 12 macro). Burn signal: the 2024–25 cost-conscious moves — distributor-led GTM instead of direct sales heads, a CEO swap to a commercialization operator, founder moved to CSO — collectively read as a capital-discipline reset, not a growth-capital deployment.
No earnings calls exist; the analog is the founder/leadership communication trail and the governance changes. The dominant data point is a two-stage leadership transition that any analyst should weight heavily:
Reading the tea leaves. A founder-CEO stepping back to CSO and an outside commercial operator being brought in is the classic "the science works, now go sell it" pivot — and, less charitably, the classic board intervention when commercialization has stalled. Montserrat's CV is specifically a commercialization-and-exit CV: Ariosa Diagnostics (built the prenatal-testing market; acquired by Roche), Omniome (NGS accuracy; acquired by PacBio), Deepcell, Splice Bio (co-founder). Boards hire that profile to either scale revenue to an IPO or dress the company for sale. The official language ("commercial scale-up," "first-class operating infrastructure built") is upbeat; the structural read is that DNA Script is past the "does the science work" question and squarely on the "can it sell enough boxes and blades to justify a $1B+ mark" question — which it has not yet publicly answered.
Tone shift over time: 2021 communications were maximalist ("first benchtop DNA printer," "DNA is the next silicon," $165M oversubscribed). 2024–26 communications are operational and incremental (distributor signings, software enhancements, "broad commercial availability of STX-200"). The narrative has descended from revolution to execution — appropriate for the stage, but the absence of a triumphant traction metric (units placed, ARR, reagent attach) in 4+ years of releases is itself the loudest thing management is not saying.
Cap-table quality — genuinely tier-1, and that is the strongest single bull point. The Series C syndicate is a who's-who of crossover and strategic capital:
The two-edged read: a crossover-heavy cap table that entered in 2021–22 at peak synbio valuations and has had no markup round since is now a liability as much as a signal — those funds carry DNA Script at a 2022 mark that the 2024–26 market almost certainly will not validate. Fidelity/T. Rowe/Baillie Gifford publish quarterly marks on private holdings; those marks for 2022-vintage synbio tools are broadly written down sector-wide (the synbio bust, Lens 12). Specific DNA Script marks are behind Caplight/PitchBook paywalls — n/a, not sourced.
Valuation (best available): DNA Script was named to France's "future unicorns" cohort (2022), implying a ~$1B+ post-money at the 2021–22 Series C. A 2026 fair value is almost certainly below that 2022 mark.
Public "comp" anchor — and the uncomfortable mirror it holds up:
| Company | Status | Market cap / valuation | Revenue | Note | Source |
|---|---|---|---|---|---|
| Twist Bioscience (TWST) | Public | $5.28B (Jun 2026) | $376.6M FY25 (+20%), guide $442–447M FY26 | The phosphoramidite incumbent EDS must displace; 13 straight quarters of sequential growth, GM ~52% | |
| Ginkgo Bioworks (DNA) | Public | ~$606M | $19M Q1'26 (down from $37M) | The synbio cautionary tale — revenue evaporated, restructuring | |
| DNA Script | Private | ~$1B (2022 mark, stale) | undisclosed | EDS pure-play, benchtop form factor |
The comp set is brutal in its honesty: Twist — the company doing centralized phosphoramidite synthesis that DNA Script's entire pitch says is the obsolete past — is a $5.3B, $377M-revenue, growing, near-breakeven business, while EDS challengers remain pre-scale. The market is paying for delivered, growing oligo revenue, not for better chemistry. EDS being technically superior has not (yet) translated into the market preferring it — the single most important fact a bull must explain away.
No public stock; the analog is the events that re-rate a private mark up or down. Pattern over the life of the company:
What the pattern reveals: the value drivers for this name are (1) the next equity round's price (up = thesis intact, flat/down = thesis impaired), (2) any disclosed installed-base/ARR metric, (3) regulatory tailwinds that make decentralized synthesis non-optional, and (4) M&A by a strategic (Danaher/Agilent/Illumina are pre-positioned). It is not earnings — there are none.
CEO — Marc Montserrat (since Feb 2025). Outside operator, deep diagnostics/life-sciences-commercial pedigree: Ariosa (→ Roche), Omniome (→ PacBio), Deepcell, co-founder Splice Bio. Track record: genuine market-creation and exit experience — exactly the skill DNA Script now needs. Skin in the game: newly granted equity (joined 2025); not a founder-sized stake. Archetype: professional-manager-as-finisher — hired to commercialize or sell, not to invent. This is appropriate for the stage and a net positive if you believe the science is done; it is also the hire a board makes when patience with the founder's commercial progress has run out.
Founder — Thomas Ybert (CEO 2014–2024, now CSO). PhD molecular biology/yeast genetics, École Polytechnique; ex-Sanofi (biotherapeutic production), ex-TotalEnergies New Energies (the Amyris biofuel collaboration — note the irony: Amyris later went bankrupt in the same synbio bust). Main inventor of EDS — the genuine technical visionary. Staying as CSO keeps the crown-jewel IP knowledge in-house (good); ceding the CEO seat is the honest acknowledgment that building the chemistry and building the company are different jobs. Co-founders Sylvain Gariel (COO) and Xavier Godron (CTO) remain — founder continuity at the operating/technical level is intact.
Capital-allocation history: raised aggressively into the 2021–22 peak (well-timed — they caught the top of the market), then shifted to capital discipline (distributor-led GTM, leaner go-to-market) as the window closed. No buybacks/dividends (private, pre-profit). The honest grade: good fundraising timing, unproven capital-efficiency on the commercial deployment — $280M raised and no disclosed revenue scale to show for it is the central unanswered question.
Red flags (governance): (1) Strategic investors who are also competitors (Danaher, Agilent, Illumina) on the cap table — common in tools, but a structural tension. (2) A 4+ year financing gap with a CEO change in the middle — the textbook pattern of a board steering a stalled commercialization toward either a rescue round or a sale. (3) No related-party or accounting red flags surfaced (and none would be visible — unaudited). Not promotional in the Ginkgo sense; communications are sober.
A forensic lens on a private company with zero public financials is necessarily about what cannot be verified, which is itself the finding. There is no audited income statement, balance sheet, or cash-flow statement in the public record [n/a — private, unaudited]. An analyst therefore cannot check revenue recognition, the reagent-vs-instrument mix, gross margin, burn rate, runway, receivables/inventory quality, or SBC dilution — every one of which is material to the thesis and all of which are dark. That opacity is the single largest analytical risk: you are underwriting a ~$1B (stale) mark on press releases.
Inference-level flags (label as such):
Regulatory findings (required sub-section).
regulatory/regulatory-findings.md (research layer, 2026-06-29) confirms total_sec_findings: 0 and notes "private and not required to file"."DNA Script" (FTC OR DOJ OR FDA OR consent decree OR settlement OR fine OR penalty) enforcement) surfaced no material enforcement actions, consent decrees, fines, or penalties against DNA Script.No EPS projection is possible (no revenue base, no guidance, private) — and per provenance discipline, none is fabricated [n/a — private]. The +private lens that matters is path-to-tradeable.
Milestones that would unlock an S-1 (none publicly cleared):
IPO-readiness assessment: LOW / not imminent. No private-watch.json entry exists to anchor a stage/readiness/catalyst, and nothing in the public record indicates an active S-1 process. The realistic 2026–28 base case is continued private operation funded by capital discipline, with a strategic acquisition (Danaher/Agilent/Illumina/Thermo) at least as likely as an IPO — possibly more likely, since a tools incumbent can fold EDS into an existing oligo franchise and a 2022-vintage cap table may prefer a clean exit to a down-round IPO. Estimated path-to-tradeable window: 2027–2029 at the earliest, IPO-or-acquisition, conditional on a disclosed recurring-revenue inflection.
(Per skill: in --watchlist mode, no Brier forecast is logged. The would-be tracked binary — "DNA Script files an S-1 or is acquired before 2028-12-31" — is noted for Connor to log via /thesis if he promotes this name; not logged here.)
Bull case. DNA Script owns the most mature benchtop enzymatic-DNA-synthesis platform on the market, backed by a genuinely tier-1 crossover + strategic cap table (Coatue, Fidelity, T. Rowe, Baillie Gifford; Illumina, Danaher, Agilent). EDS is the structurally superior chemistry — mild, aqueous, fast, and the only approach that runs on a benchtop — which opens a market phosphoramidite physically cannot serve: decentralized, same-day, sequence-confidential synthesis. Two secular tailwinds compound the thesis: (1) biosecurity regulation (EO 14292, IBBIS, S.3741) increasingly favors keeping synthesis inside the institution's perimeter, which is exactly what an on-site printer does; (2) the mRNA/therapeutics and (longer-dated) DNA-data-storage markets need cheap, fast, distributed DNA-writing — DNA Script's Moderna/DARPA and EVA Pharma partnerships pre-position it. A commercialization-proven CEO (Montserrat) is now driving GTM with capital-light distribution. If the reagent annuity inflects, this is a high-margin razor-and-blades franchise that a strategic pays up for.
Bear case (the 2–3 that permanently impair):
Pre-mortem (it's late 2027, the thesis broke — what happened?): DNA Script ran low on the 2022 round in 2026–27, couldn't raise a flat/up round in a still-frozen synbio market, and either (a) took a punishing down-round that wiped the crossover holders, or (b) sold to Agilent/Danaher for ~the cash raised — a soft landing, not the "DNA-is-the-next-silicon" outcome. Meanwhile IDT/Ansa captured the enzymatic-at-scale market, relegating SYNTAX to a niche benchtop tool with a modest installed base that never reached the reagent-annuity inflection.
Is the (stale) ~$1B mark too high? Yes, almost certainly — a 2022 synbio-peak private mark with no markup and no disclosed revenue, against a sector that has de-rated 40–70%, is not a 2026 clearing price.
Contrarian view (what the market refuses to see): the bear consensus ("synbio is dead, EDS lost to Twist") may under-price the biosecurity optionality. If S.3741 / EO-14292 evolves toward mandatory in-perimeter synthesis screening or sequence-confidentiality requirements for sensitive work (defense, select-agent, pharma IP), on-site benchtop synthesis flips from "nice-to-have niche" to "compliance-required infrastructure" — and DNA Script is the only mature benchtop option. That is a low-probability, high-payoff tail the gloom ignores. It is optionality, not a base case.
Dismantling the bull case. Where does the money actually come from? Nobody outside the company knows — and in synbio, undisclosed revenue is a red flag, not a neutral. Ginkgo's entire revenue turned out to be related-party round-tripping; the default skeptic prior on an opaque synbio-tools name is "show me the recurring third-party revenue or I assume there isn't much." Revenue concentration: the only named relationships (Moderna/DARPA — up to $5M, EVA Pharma — ecosystem) are strategic and small; if commercial revenue is concentrated in a handful of grant-adjacent or flagship accounts, the "annuity" is a story, not a P&L. Why the moat is weaker than bulls think: the moat is a benchtop instrument — but the customer's real alternative is not buying an instrument at all and ordering from Twist/IDT at lower all-in cost; the switching cost only binds the minority who buy in. The most dangerous competitor bulls underestimate: not another startup — it's IDT (Danaher), which has the incumbent oligo franchise, global manufacturing, and now an enzymatic partner (Ansa); and Twist, which can add enzymatic chemistry to a $377M revenue base if/when benchtop demand proves real. A $5B incumbent fast-following a $1B startup's niche is the startup's nightmare. Worst capital-allocation read: raised $280M at the top and has no disclosed commercial scale 4 years later — that is either heavy burn for thin output, or output they won't disclose because it's unflattering. What must hold for today's (stale) mark: that benchtop EDS becomes a mass lab-standard, that the reagent annuity is large and growing, and that a frozen IPO/M&A market re-opens at 2022 prices — three things, none evidenced. Growth disappoints 20–30%? There's no public growth number to disappoint from — which for a short-seller is the point: un-falsifiable bull stories are the ones that end in down-rounds. Single scenario that permanently impairs: the 2022 round runs out before a markup is achievable, forcing a distressed sale or recap that zeroes the equity story. Plausibility: moderate-to-high given the financing gap and macro.
Not a tools company anymore — a sub-NAV cash shell mid-conversion into Treeline's oncology pipeline; the only edge is the deal-spread between ~$325M market cap and the ~$460M net cash being delivered, and that spread is a bet on Bilenker's KRAS/BCL6 readouts, not on CyTOF.
A re-rated single-asset AI-antibody story — ABS-101's half-life miss quietly killed the old lead, so the entire ~$1.15B cap now rides on one binary (ABS-201 alopecia interim PoC, H2 2026) against a 26%-of-float short and an 18-month runway. Own the readout, not the platform.
A fortress-margin vertical-SaaS monopoly trading at a growth-stock funeral price (~20x forward EPS, near 52-wk lows) because the market is pricing a Salesforce-Agentforce CRM war that threatens the contested ~40% (Commercial) while ignoring the defensible, faster-growing ~60% (R&D/Quality); BULLISH at $153 on a 1–3Y view, but the CRM-migration-to-2030 is a real, watchable execution overhang — not a phantom.